How has the recent FDA approval of tovorafenib impacted your treatment decisions for pediatric patients with relapsed/refractory low-grade glioma?

With the FDA approval, and given the tolerability of therapy and the pediatric friendly once weekly dosing and formulations, I will prescribe tovorafenib regularly for my patients with relapsed refractory low grade glioma. I do think it will become a standard choice in this setting. That said, given...

If we look at the current landscape, tovorafenib is - in the USA - the only targeted therapy approved for the second-line treatment of BRAF-altered pLGG. So, this is a great opportunity for patients. There is no MEK inhibitor approved in this setting (trametinib, selumetinib, binimetinib, mirdametin...